^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Solid Tumor
    Drug:anbenitamab (KN026) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

    Excerpt:
    ...Unresectable locally advanced, recurrent or metastatic gastric cancer (including gastric-esophageal junction adenocarcinoma) confirmed by histopathology and/or cytology; HER2 positive expression is defined as IHC 3+ or IHC 2+ with ISH test positive....
    Trial ID:
    NCT05427383
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oxford Academic
    Title:

    PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION

    Published date:
    07/24/2023
    Excerpt:
    4 of 21 pts (1 at 10mg/kg, 2 at 20 mg/kg, 1 at 30mg/kg) achieved objective response (ORR 19.0%, 95% CI: 5.5, 41.9), and DCR was 61.9% (95% CI: 38.4, 81.9)….KN026 was well tolerated and showed the promising anti-tumor activity in US pts with HER2 expression.
    DOI:
    https://doi.org/10.1093/abt/tbad014.006
    Trial ID:
    NCT03847168